title: Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment--the COMPAS study.
abstract: BACKGROUND
  It is known that suboptimal adherence rates may affect endocrine treatments for breast cancer, but little information has been reported whether any efforts to improve treatment adherence have been successful. We designed a randomized, controlled study to investigate the effect of oral or written patient information program on adherence and persistence when receiving an aromatase inhibitor (AI).
  
  
  METHODS
  The study cohort included 181 female patients receiving an adjuvant AI treatment randomly assigned to one of three groups. The first group received reminder letters and information booklets, the second group was reminded and informed through telephone calls and the control group received neither. The primary endpoint was the rate at which patients were classified as adhering to treatment after twelve months.
  
  
  RESULTS
  Baseline results showed a well-balanced randomization with no significant differences between groups. After 12 months, 48% (CI 35-62) of the control group, 62.7% (CI 49-75) in the telephone group and 64.7% (CI 51-77) in the letter group were adhering to therapy. A post hoc pooled analysis with a one-way hypothesis for both interventions versus control indicated a significant difference between the groups favouring the intervention (p = 0.039).
  
  
  CONCLUSIONS
  The aim of this study was to investigate the efficacy of a simple and practical interventional program in enhancing adherence to breast cancer treatment. Patients receiving additional/supplemental information appeared to have an improved adherence rate even though the differences between groups were not statistically significant for the primary endpoint.
authors.affiliation: Department of Gynecology, University hospital of Giessen and Marburg GmbH, Marburg, Baldingerstrasse, 35033 Marburg, Germany. ziller@med.uni-marburg.de.
authors.forename: Volker
authors.initials: V
authors.lastname: Ziller
authors.forename: Ioannis
authors.initials: I
authors.lastname: Kyvernitakis
authors.forename: Dana
authors.initials: D
authors.lastname: Knöll
authors.forename: Astrid
authors.initials: A
authors.lastname: Storch
authors.forename: Olaf
authors.initials: O
authors.lastname: Hars
authors.forename: Peyman
authors.initials: P
authors.lastname: Hadji
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D055118:Medication Adherence; D008875:Middle Aged; D009367:Neoplasm Staging; D010353:Patient Education as Topic; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors